ENTPD1 and neoplasm: This is supported by preclinical murine tumor models in which CD39 blockade with IPH5201 or genetic deletion of CD39 increased the antitumor activity of an anti–PD-1 mAb or an ATP-inducing chemotherapeutic drug (3).